Improvement of outcome and reduction of toxicity in elderly patients with CD20+aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody Rituximab, substitution of conventional by liposomal Vincristine, and FDG-PET based reduction of therapy in combination with vitamin D substitution (#575)